Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 1998

View Archived Issues

Company Profile: IgX

New compounds synthesized at HMR upregulate LDL receptors

Schering-Plough presents new agents for cognitive disorders

Recent data suggest mechanism of action of nefiracetam's beneficial effects on cognition

Genentech receives fast track product designation for Herceptin

Novel liposomal delivery system available for licensing from NCI/NIH

MGI Pharma presents MGI-114 data at AACR

BioTime files NDA for blood plasma volume expander

Nefiracetam: a potential treatment for PCP addiction?

TAPET efficacy reported at AACR meeting

Dramatic anticancer activity observed with FGN-1 in animal models

Broad-spectrum antibacterial agents synthesized by Daiichi

MGI now distributing Salagen for Sjogren's syndrome in U.S.

Mochida prepares novel agents for disorders associated with eosinophilia

Banyu develops factor Xa inhibitors as antiplatelet/antithrombotic agents

Cardioprotective effects of new Lederle compound assessed

Merck KGaA initiates worldwide cancer study with BEC2

TheraTech, Palatin collaborate on oral peptides; first product will be a new treatment for ED

Preclinical data indicates efficacy of AltaRex's approach to cancer immunotherapy

Neurex completes patient enrollment in ziconotide phase III trial

Protein farnesyltransferase inhibitor advanced to clinical trials by Schering-Plough

Liposomal telomerase antisense oligonucleotide effective alone and in combination

Chiron obtains full ownership of Chiron Behring

Merck & Co. identifies orally active, short-acting GH secretatogue

Research at Pfizer leads to potent CysLT1 antagonist

N-Alkylated saccharins from Merck & Co. with potential in BPH therapy

NTE-122: effects on lipid metabolism and secretion in vitro

GH secretagogue shows beneficial cardiovascular activity in rats

Mechanism of vasorelaxant effects of HFV-1017C elucidated

FR-146801 inhibits intimal thickening in a rat balloon injury model